<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Catheter Precision, Inc. Secures up to $36.5 Million in Strategic Institutional Financing to Accelerate Growth</title>
<style>
body { font-family: Arial, Helvetica, sans-serif; background:#0f1115; color:#e6e6e6; margin:0; padding:40px; }
.container { max-width:700px; margin:auto; background:#161a21; border-radius:10px; padding:32px; box-shadow:0 0 30px rgba(0,0,0,0.4); }
h1 { margin-top:0; color:#4da3ff; }
table { width:100%; margin-top:12px; border-collapse:collapse; }
th, td { text-align:left; padding:6px 8px; border-bottom:1px solid #2a2f3a; }
ul { margin-top:12px; padding-left:20px; }
.section { margin-top:24px; }
.small { margin-top:12px; font-size:13px; color:#999; }
a { color:#4da3ff; }
</style>
</head>
<body>
  <div class="container">
    <h1>Catheter Precision, Inc. Secures up to $36.5 Million in Strategic Institutional Financing to Accelerate Growth</h1>

    <table>
      <tr><th>Ticker</th><td>VTAK</td></tr>
      <tr><th>Float</th><td>1.6 M</td></tr>
      <tr><th>IO</th><td>1.03%</td></tr>
      <tr><th>MC</th><td>3.2 M</td></tr>
      <tr><th>Extra Info</th><td>None</td></tr>
    </table>

    <div class="section">
      <strong>Summary</strong>
      <p>Catheter Precision (NYSE: VTAK) announced the termination of its at‑the‑market (ATM) equity program and completion of a strategic institutional financing providing up to $36.5 million to support accelerated growth. The company said no future equity lines or forward‑priced agreements are anticipated. As part of the financing and balance sheet restructuring, short‑term notes were extended to two‑ and three‑year maturities and approximately $9 million of additional short‑ and long‑term liabilities reported on the 9/30/25 balance sheet are being converted into equity. The company referenced related Form 8‑K filings dated February 6 and February 12, 2026.</p>
    </div>

    <div class="section">
      <strong>Positives</strong>
      <ul><li>Secured up to $36.5 million in strategic institutional financing</li><li>Termination of ATM equity offering program (no future equity lines or forward‑priced agreements anticipated)</li><li>Balance sheet and liquidity described as significantly strengthened</li><li>Short‑term notes converted to longer maturities (two and three years)</li><li>Approximately $9 million of liabilities being converted into equity, reducing certain liabilities on the balance sheet</li><li>Company aligned with institutional investors per CEO commentary</li></ul>
    </div>

    <div class="section">
      <strong>Negatives</strong>
      <ul><li>Company had outstanding short‑term notes and additional short‑ and long‑term liabilities (≈$9 million on 9/30/25) prior to the restructuring</li><li>The announcement contains forward‑looking statements subject to risks and uncertainties (per the cautionary note)</li></ul>
    </div>

    <div class="section">
      <a href="https://news.nuntiobot.com/article/9cec9b8f-caac-4d26-a729-9418af604123" target="_blank">Original Article</a>
    </div>

    <div class="small">VTAK • TradersLink AI News</div>
  </div>
</body>
</html>